Topcon
7732
TEMONA
3985
Forside
2330
Okamoto Glass
7746
Delta-Fly Pharma
4598
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 17.61%56.94B | 2.29%213.9B | 8.49%55.4B | 7.73%60.08B | -4.30%50.01B | -3.22%48.42B | 4.98%209.11B | -1.70%51.06B | 6.20%55.76B | 5.45%52.26B |
Cost of revenue | 11.77%48.01B | 0.89%184.94B | 8.57%47.62B | 3.95%51.09B | -6.41%43.27B | -2.51%42.96B | 5.45%183.31B | -4.10%43.86B | 7.91%49.14B | 6.33%46.24B |
Gross profit | 63.67%8.93B | 12.26%28.97B | 7.98%7.78B | 35.84%8.99B | 11.95%6.74B | -8.46%5.46B | 1.76%25.8B | 16.01%7.2B | -5.00%6.62B | -0.86%6.02B |
Operating expense | 5.45%4.06B | 5.31%16.14B | 12.90%4.3B | 6.71%4.1B | 0.39%3.89B | 1.29%3.85B | 0.07%15.33B | -13.46%3.81B | 2.59%3.85B | 6.67%3.87B |
Staff costs | ---- | 4.90%8.29B | ---- | ---- | ---- | ---- | 25.32%7.9B | ---- | ---- | ---- |
Selling and administrative expenses | ---- | -0.44%1.35B | ---- | ---- | ---- | ---- | -6.89%1.35B | ---- | ---- | ---- |
-Selling and marketing expense | ---- | 0.00%25M | ---- | ---- | ---- | ---- | -44.44%25M | ---- | ---- | ---- |
-General and administrative expense | ---- | -0.45%1.32B | ---- | ---- | ---- | ---- | -5.69%1.33B | ---- | ---- | ---- |
Research and development costs | ---- | 16.92%1.32B | ---- | ---- | ---- | ---- | -3.09%1.13B | ---- | ---- | ---- |
Depreciation and amortization | ---- | 1.84%775M | ---- | ---- | ---- | ---- | 2.42%761M | ---- | ---- | ---- |
-Depreciation | ---- | 1.84%775M | ---- | ---- | ---- | ---- | 2.42%761M | ---- | ---- | ---- |
Other operating expenses | ---- | 5.43%4.41B | ---- | ---- | ---- | ---- | -26.00%4.18B | ---- | ---- | ---- |
Operating profit | 203.49%4.87B | 22.43%12.83B | 2.47%3.48B | 76.24%4.89B | 32.73%2.86B | -25.64%1.6B | 4.35%10.48B | 87.67%3.4B | -13.83%2.77B | -12.01%2.15B |
Net non-operating interest income (expenses) | -9.09%-108M | 10.80%-355M | 30.28%-76M | 50.86%-57M | -24.24%-123M | -33.78%-99M | -50.19%-398M | -62.69%-109M | -70.59%-116M | -52.31%-99M |
Non-operating interest income | -43.18%25M | 84.43%225M | 90.63%61M | 196.77%92M | -12.50%28M | 62.96%44M | 24.49%122M | 39.13%32M | 14.81%31M | 28.00%32M |
Non-operating interest expense | -6.99%133M | 11.54%580M | -2.84%137M | 1.36%149M | 15.27%151M | 41.58%143M | 43.25%520M | 56.67%141M | 54.74%147M | 45.56%131M |
Net investment income | -98.81%1M | 651.43%263M | -7.79%142M | 26.79%-41M | 368.97%78M | 347.06%84M | -69.30%35M | 123.19%154M | -280.65%-56M | -180.56%-29M |
Gain(Loss) on financial instruments designated as cash flow hedges | -910.00%-162M | -238.78%-166M | -83.19%20M | 72.63%-49M | ||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 841.67%1.36B | 1,367.92%778M | 24M | 367.16%179M | 137.34%375M | 251.22%144M | 381.82%53M | 0 | -67M |
Income from associates and other participating interests | -102.00%-1M | -87.45%33M | -197.45%-153M | 110.00%2M | 157.69%134M | -32.43%50M | -45.66%263M | -3.09%157M | -122.73%-20M | -50.00%52M |
Special income (charges) | 85.21%-25M | -126.95%-563M | 58.12%-258M | -115.43%-98M | -101.83%-38M | -2,012.50%-169M | 70.53%2.09B | -130.71%-616M | 275.90%635M | 1,053.21%2.08B |
Less:Restructuring and mergern&acquisition | -85.21%25M | 13.17%464M | -44.01%159M | 292.00%98M | -53.09%38M | 745.00%169M | -53.36%410M | 189.80%284M | -93.07%25M | -62.84%81M |
Less:Other special charges | ---- | 103.61%99M | ---- | ---- | ---- | ---- | -30.37%-2.74B | --88M | ---660M | ---2.16B |
Less:Write off | ---- | --0 | ---- | ---- | ---- | ---- | --244M | ---- | ---- | ---- |
Other non-operating income (expenses) | 155.00%33M | -244.95%-287M | -189.58%-86M | -38.98%-82M | -149.58%-59M | -242.86%-60M | 232.89%198M | 323.26%96M | 24.36%-59M | 1,181.82%119M |
Income before tax | 155.21%4.6B | 2.73%13.1B | 18.89%3.66B | 46.68%4.63B | -26.32%3.01B | -25.91%1.8B | 12.77%12.76B | -18.37%3.08B | 10.46%3.16B | 80.09%4.09B |
Income tax | 162.78%1.51B | 24.22%3.82B | 3,718.52%1.03B | 260.31%1.42B | -60.42%794M | -10.99%575M | 66.05%3.07B | 107.94%27M | -51.00%393M | 172.55%2.01B |
Net income | 151.67%3.09B | -4.10%9.29B | -13.88%2.63B | 16.31%3.22B | 6.43%2.22B | -31.26%1.23B | 2.36%9.68B | -25.79%3.05B | 34.48%2.77B | 35.70%2.08B |
Net income continuous operations | 151.67%3.09B | -4.09%9.29B | -13.88%2.63B | 16.31%3.22B | 6.53%2.22B | -31.30%1.23B | 2.35%9.68B | -25.79%3.05B | 34.42%2.77B | 35.72%2.08B |
Noncontrolling interests | 232.65%163M | 64.47%449M | 117.31%113M | 178.46%181M | 1,225.00%106M | -66.89%49M | 152.78%273M | 360.00%52M | 3,150.00%65M | -90.24%8M |
Net income attributable to the company | 148.22%2.93B | -6.08%8.84B | -16.15%2.51B | 12.41%3.04B | 1.78%2.11B | -28.05%1.18B | 0.61%9.41B | -27.42%3B | 31.45%2.7B | 42.84%2.07B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 148.22%2.93B | -6.08%8.84B | -16.15%2.51B | 12.41%3.04B | 1.78%2.11B | -28.05%1.18B | 0.61%9.41B | -27.42%3B | 31.45%2.7B | 42.84%2.07B |
Gross dividend payment | ||||||||||
Basic earnings per share | 151.27%99.2 | -5.68%297.12 | -15.27%84.98 | 12.99%102.09 | 1.64%70.57 | -28.14%39.48 | 0.50%315.01 | -27.49%100.29 | 31.27%90.35 | 42.65%69.43 |
Diluted earnings per share | 151.27%99.2 | -5.68%297.12 | -15.24%84.98 | 12.99%102.09 | 1.64%70.57 | -28.14%39.48 | 0.50%315.01 | -27.51%100.2615 | 31.27%90.35 | 42.65%69.43 |
Dividend per share | 0 | 50.00%90 | -8.33%55 | 0 | 35 | 0 | 20.00%60 | 20.00%60 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |